SCHEMBL4019784

SCHEMBL4019784

N#Cc1cccc(C(=O)NC2CCN(c3ncnc4cc(Cl)ccc34)CC2)c1.O=C(NC1CCN(c2ncnc3cc(Cl)ccc23)CC1)c1cc(F)cc(F)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SUV39H1 O43463 2/20 0.47
PRMT1 Q99873 2/20 0.47
SMYD3 Q9H7B4 2/20 0.47
PAK1 Q13153 4/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CCNE1 P24864 2/20 0.43
CDK2 P24941 2/20 0.43
LRRK2 Q5S007 1/20 0.43
GRM5 P41594 3/20 0.43
CNR1 P21554 3/20 0.42
CNR2 P34972 3/20 0.42
ADRA2A P08913 1/20 0.41
MCHR1 Q99705 1/20 0.41
AR P10275 1/20 0.41
JAK3 P52333 1/20 0.40
MAP3K6 O95382 1/20 0.40
MAP3K5 Q99683 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021891 0.94 SUV39H1 (0.52) SUV39H1PRMT1SMYD3PAK1CYP1A2
SCHEMBL4023489 0.89 CYP1A2 (0.56) SUV39H1PRMT1SMYD3PAK1CYP1A2
SCHEMBL4024379 0.88 CCNE1 (0.47) CCNE1CDK2GRM5AR
SCHEMBL4024378 0.85 CYP1A2 (0.57) SUV39H1PRMT1SMYD3PAK1CYP1A2
SCHEMBL4017884 0.82 PAK1 (0.63) SUV39H1PRMT1SMYD3PAK1CYP1A2
SCHEMBL4018937 0.81 ALDH1A1 (0.52) GRM5
SCHEMBL4023998 0.81 CYP1A2 (0.53) SUV39H1PRMT1SMYD3PAK1CYP1A2
SCHEMBL4022823 0.81 CYP1A2 (0.53) SUV39H1PRMT1SMYD3PAK1CYP1A2
SCHEMBL4019432 0.81 CNR1 (0.57) SUV39H1PRMT1SMYD3PAK1CYP1A2
SCHEMBL4582908 0.81 GRM5 (0.49) PAK1CCNE1CDK2LRRK2GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2066654-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS Bayer Schering Pharma AG (DE) 2009-06-10 EP claimed
WO-2008028691-A1 N-(1-HETARYLPIPERIDIN-4-YL)(HET)ARYLAMIDES AS EP2 RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-13 WO claimed